ATE126698T1 - Verwendung eines phagozytise-aktievierenden stoffes : lps oder il-2 zur herstellung eines arzneimittels zur behandlung von staphylococcus- aureus-infektionen bei kühen. - Google Patents

Verwendung eines phagozytise-aktievierenden stoffes : lps oder il-2 zur herstellung eines arzneimittels zur behandlung von staphylococcus- aureus-infektionen bei kühen.

Info

Publication number
ATE126698T1
ATE126698T1 AT90111644T AT90111644T ATE126698T1 AT E126698 T1 ATE126698 T1 AT E126698T1 AT 90111644 T AT90111644 T AT 90111644T AT 90111644 T AT90111644 T AT 90111644T AT E126698 T1 ATE126698 T1 AT E126698T1
Authority
AT
Austria
Prior art keywords
phagocytic
phagocytis
lps
cows
producing
Prior art date
Application number
AT90111644T
Other languages
English (en)
Inventor
Michael Joseph Daley
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE126698T1 publication Critical patent/ATE126698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
AT90111644T 1989-06-30 1990-06-20 Verwendung eines phagozytise-aktievierenden stoffes : lps oder il-2 zur herstellung eines arzneimittels zur behandlung von staphylococcus- aureus-infektionen bei kühen. ATE126698T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37433989A 1989-06-30 1989-06-30

Publications (1)

Publication Number Publication Date
ATE126698T1 true ATE126698T1 (de) 1995-09-15

Family

ID=23476360

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90111644T ATE126698T1 (de) 1989-06-30 1990-06-20 Verwendung eines phagozytise-aktievierenden stoffes : lps oder il-2 zur herstellung eines arzneimittels zur behandlung von staphylococcus- aureus-infektionen bei kühen.

Country Status (6)

Country Link
EP (1) EP0405315B1 (de)
AT (1) ATE126698T1 (de)
DE (1) DE69021791T2 (de)
DK (1) DK0405315T3 (de)
ES (1) ES2076259T3 (de)
GR (1) GR3017258T3 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO116459B1 (ro) * 1991-07-25 2001-02-28 Idec Pharma Corp Compozitie imunogena
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5641875A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania DNA encoding chimeric IgG Fc receptor
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
DK1449535T3 (da) 2003-02-18 2006-09-11 Clinique La Prairie Res Sa Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
WO2007037099A1 (ja) 2005-09-27 2007-04-05 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 乳房炎の治療剤
WO2008106763A1 (en) * 2007-03-08 2008-09-12 The Governors Of The University Of Alberta Bacterial endotoxin for the prevention of metabolic disorders and bacterial infections
JP2010540892A (ja) * 2007-09-24 2010-12-24 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー 抗炎症活性を有する化合物をスクリーニングする方法
FI20085812A0 (fi) * 2008-09-01 2008-09-01 Esa-Matti Lilius Karkea LPS immunostimulanttina vesiviljelyssä
US20140088032A1 (en) * 2011-05-12 2014-03-27 Thomas Simon Ilg Treatment of mastitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2528703A1 (fr) * 1982-06-16 1983-12-23 Lacombe Jean Francois Nouveau medicament veterinaire destine au traitement des mammites infectieuses des bovins et des caprins a base de polymyxine, d'erythromycine et de lysozyme
US4882282A (en) * 1985-08-16 1989-11-21 Immunex Corporation DNA sequences encoding bovine interleukin-2
GB8628826D0 (en) * 1986-12-02 1987-01-07 Beecham Group Plc Pharmaceutical products
PH24467A (en) * 1987-03-03 1990-07-18 Hem Res Inc Synergistics interplay of lymphokines and dsrnas
US4938956A (en) * 1987-04-01 1990-07-03 International Minerals & Chemical Corp. Synergistic immunostimulating composition and method
AU623864B2 (en) * 1988-08-29 1992-05-28 Applied Microbiology, Inc Method of treating mastitis and other staphylococcal infections

Also Published As

Publication number Publication date
DE69021791T2 (de) 1996-05-02
EP0405315A3 (en) 1991-03-20
EP0405315B1 (de) 1995-08-23
DE69021791D1 (de) 1995-09-28
DK0405315T3 (da) 1995-09-25
EP0405315A2 (de) 1991-01-02
GR3017258T3 (en) 1995-11-30
ES2076259T3 (es) 1995-11-01

Similar Documents

Publication Publication Date Title
DE3688841T2 (de) Schwache interferondosierung für die erhöhung der impfstoffwirksamkeit.
ATE150616T1 (de) Verabreichungszusammensetzungen für unkrautvertilgungsmittel sowie verfahren zur regelung der pflanzenbevölkerung in wässriger und sumpfähnlicher umgebung
DE3876123D1 (de) Insektizideabgabezusammensetzungen und verfahren zur bekaempfung einer insektenpopulation in einer waessrigen umgebung.
ATE126698T1 (de) Verwendung eines phagozytise-aktievierenden stoffes : lps oder il-2 zur herstellung eines arzneimittels zur behandlung von staphylococcus- aureus-infektionen bei kühen.
DK166763C (da) Immunoglobulin-g-holdig fraktion
EP0308197A3 (de) Verfahren zur Stimulierung des Immunsystems
DE69632396D1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
Blagbum et al. Efficacy dosage titration of lufenuron against developmental stages of fleas (Ctenocephalides felis felis) in cats
DE3777973D1 (de) Tiermedizinische behandlung.
Denis et al. Modulation of Mycobacterium avium Growth in Murine Macrophages: Reversal of Unresponsiveness to Interferon‐Gamma by Indomethacin or Interleukin‐4
Howard et al. The effects of triflumuron, a chitin synthesis inhibitor, on the housefly, Musca domestica (Diptera: Muscidae)
EP1973560A2 (de) Rinderosteopontin-formulierungen zur verbesserung des wundheilungsprozesses
RU2102070C1 (ru) Способ профилактики гиподерматоза крупного рогатого скота
Moloo et al. Suppressive action of Samorin on the cyclical development of pathogenic trypanosomes in Glossina morsitans centralis
AU4519189A (en) Medicaments for the treatment of toxoplasmosis
FI833729A0 (fi) Bete foer gnagare
FR2529213B1 (fr) Derive keratinique, son procede de preparation et composition de traitement le contenant
RU2149602C1 (ru) Способ аэрозольной обработки цыплят
DE19512227C1 (de) Multifaktorielles Abwehr-Modulatorengemisch, Verfahren zu seiner Herstellung und diese Modulatoren enthaltende Arzneimittel
RU2846896C1 (ru) Антимикробный препарат и способ его получения
RU2011380C1 (ru) Способ профилактики и лечения некробактериоза животных
Graham Tests with Bayer 21/199 for the control of cattle grubs
BR9611722A (pt) Processo para reduzir reações adversas a um inseticida por um animal e para proteger um animal de infestação por exctoparasitas
US3622664A (en) Treatment of infectious keratitis in animals with sodium arsenite
Kurek et al. Biological method of control of staphylococcal infections of udders in a herd of cows in a dry period.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee